11:03 AM EST - Microbix Biosystems Inc. : Announces execution of an agreement to return Kinlytic urokinase to market, initially for dissolving blood clots in venous catheters in the United States and to be followed by other geographies and clinical indications. Its Agreement is with Sequel Pharma, LLC, a specialty pharma company with expertise in developing and commercializing drugs for the U.S. market that is funded by a leading private equity firm. Microbix Biosystems Inc.
shares T.MBX are trading up $0.07 at $0.44.
